37 results on '"Noesslinger, T."'
Search Results
2. Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes
3. Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group
4. SAFETY AND EFFECTIVENESS OF VENETOCLAX MONOTHERAPY IN ELDERLY PATIENTS WITH RELAPSED/REFRACTORY CLL UNDER REAL‐LIFE CONDITIONS – DATA FROM THE OBSERVATIONAL STUDY VERVE
5. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q
6. Data from the German-Austrian-Suisse MDS registry (D-A-CH MDS registry): V954
7. Critical analysis and validation of the Azacitidin Prognostic Scoring System (APSS): V957
8. Cytogenetic Risk Features in MDS - Update and Present State: V371
9. Beneficial effect of high-dose chemotherapy in multiple myeloma patients with unfavorable prognostic features
10. DYSPLASTIC VS. PROLIFERATIVE CMML - RETROSPECTIVE ANALYSIS OF 92 PATIENTS FROM A SINGLE INSTITUTION
11. P061 Concordant regulation of estrogen receptor, fat metabolism and osteocalcin in myelodysplastic syndromes
12. P018 Host related features explain heterogeneity in risk groups of disease related scoring systems in MDS
13. P020 Refining prognostic systems by comorbidity: are existing scores sufficient for MDS or may specific scores perform better?
14. P028 Survival, prognostic factors, and leukemic transformation in a multicenter study of 241 patients with MDS and del(5q)
15. P019 Time changes in predictive power of established and recently proposed clinical, cytogenetic, and co-morbidity scores in MDS
16. 12 Updated cytogenetic risk features in MDS – present state
17. P007 Attempts to define a No Risk subgroup in MDS by examining relative survival in well known scoring systems
18. C005 Prognostic impact of the proportion of aberrant metaphases in patients with a primary myelodysplastic syndrome
19. PROGNOSTIC IMPACT OF ADDITIONAL CHROMOSOMAL ABERRATIONS TO 5Q-IN PATIENTS WITH PRIMARY MYELODYSPLASTIC SYNDROMES
20. 154 Some determinants of disease specific mortality in MDS
21. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q
22. Myelodysplastische Syndrome: klinisch relevante Aspekte in Diagnostik, Prognose und Prädiktion
23. P-111 Time changes in predictive power of MDS prognostic scores – Effects on revised scores such as the IPSS-R, impact of age
24. Infusion reactions to the chimeric EGFR inhibitor cetuximab—change to the fully human anti-EGFR monoclonal antibody panitumumab is safe
25. 314 Prognostic impact of cytopenias in MDS – progress beyond the currently used cut-point concept
26. 318 A novel score optimized for accurate prediction of survival in patients with de novo myelodysplastic syndromes
27. P119 The integration of comorbidity in decision making in myelodysplastic syndromes
28. P110 Individualized IPSS in MDS by considering age, gender and FAB – a multicenter analysis
29. P064 Downregulation of microsomal carnitine palmitoyltransferase (mCPT) in myelodysplastic syndromes (MDS) – induced by hypermethylation and/or reduced carnitine availability
30. C013 The influence of therapeutic strategies on survival in distinct cytogenetic subgroups – A collaborative study based on 3860 patients with MDS
31. Correlation of Cytogenetic Findings with Morphology, Clinical Course and Prognosis in 2124 Patients with MDS.
32. 55 Prognosis in myelodysplastic syndromes with specific reference to karyotypes — Experience on 296 patients from a single institution
33. Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders.
34. High-dose Bendamustine-EAM followed by autologous stem cell rescue results in long-term remission rates in lymphoma patients, without renal toxicity.
35. A phase I study of lenalidomide in patients with chronic myelomonocytic leukemia (CMML) - AGMT_CMML-1.
36. Evaluation of the prognostic significance of eosinophilia and basophilia in a larger cohort of patients with myelodysplastic syndromes.
37. [Myelodysplastic syndromes: clinically relevant aspects in diagnosis, prognosis and prediction].
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.